Putnam Investments’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Putnam Investments’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-52,227	Closed	-$2.88M	–	883
2020 Q3	$2.88M	Buy	52,227 +1,807	+4%	+$115K	0.01%	568
2020 Q2	$3.18M	Buy	50,420 +8,433	+20%	+$578K	0.01%	550
2020 Q1	$2.15M	Sell	41,987 -19,375	-32%	-$1.3M	0.01%	599
2019 Q4	$4.88M	Hold	61,362	–	–	0.01%	510
2019 Q3	$2.98M	Buy	61,362 +119	+0.2%	+$6.2K	0.01%	632
2019 Q2	$3.22M	Buy	61,243 +32	+0.1%	+$1.84K	0.01%	632
2019 Q1	$3.24M	Hold	61,211	–	–	0.01%	617
2018 Q4	$2.51M	Buy	61,211 +4,869	+9%	+$182K	0.01%	598
2018 Q3	$2.14M	Buy	56,342 +37,498	+199%	+$1.66M	﹤0.01%	751
2018 Q2	$852K	Sell	18,844 -2,998	-14%	-$137K	﹤0.01%	879
2018 Q1	$1.05M	Buy	+21,842	New	+$1.22M	﹤0.01%	852
2015 Q4	–	Sell	-43,162	Closed	-$1.82M	–	1506
2015 Q3	$1.82M	Buy	+43,162	New	+$2.04M	﹤0.01%	1019

Other funds holding GBT

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Putnam Investments's GBT Position: Q4 2020 in Review

Putnam Investments sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2020, closing a stake of 52,227 shares — an estimated $2.88M sold.

Putnam Investments first reported a position in GBT in Q3 2015 and held it in 12 quarters. The position peaked at $4.88M in Q4 2019. 228 funds tracked by Wall St. Rank hold GBT as of Q4 2020.

Putnam Investments reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
Putnam Investments sold 52,227 Global Blood Therapeutics, Inc. shares in Q4 2020, an estimated $2.88M.
Putnam Investments first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 12 quarters.
Putnam Investments's Global Blood Therapeutics, Inc. position peaked at $4.88M in Q4 2019.
228 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2020.

Based on Putnam Investments's 13F filing for Q4 2020, filed 16 Feb 2021.